Achillion Kicks Off Dosing Trial for Hepatitis C Drug
Achillion begins anti-hepatitis drug trials
New Haven drug developer Achillion Pharmaceuticals Inc. says it has begun two human clinical trials in the U.S. and Europe to determine the dosing effectiveness of a prototype treatment against the hepatitis C virus.
Some 120 patients with chronic hepatitis C participating in the two double-blind trials — one to run 28 days, the other 12 weeks — will be randomly dosed with small-molecule ACH-1625 drug or with a placebo.
Continue reading this entire article: